Enzyme-linked Immunosorbent Assay Market Analysis

Type (Indirect ELISA, Sandwich ELISA)

In enzyme-linked immunosorbent assay market, sandwich ELISA segment is likely to account for around 62% share by 2037. Collaborations between academic institutions, biotechnology companies, and pharmaceutical firms foster innovation in biomarker research, thus, Sandwich ELISA, being a cornerstone in this field, benefits from such partnerships.

The shared expertise and resources in collaborative projects contribute to the development and validation of sandwich ELISA assays, further propelling its market growth. A study found that strategic collaborations in the life sciences industry have increased by over 30% in recent years. The growth of the sandwich ELISA segment is further driven by the rising demand for cancer biomarkers, advancements in precision medicine, increasing investment in biomarker research, the clinical emphasis on disease monitoring, growing pharmaceutical research activities, and strategic alliances and collaborations in the life sciences industry.

End User (Hospitals, Pharmaceutical, Research & Academic Institutions)

In terms of end users, the hospital segment is likely to cross a significant share during the studied period. The shift towards personalized medicine involves tailoring medical decisions and interventions based on individual patient characteristics.

Hospitals are increasingly adopting personalized approaches to improve treatment efficacy, leading to the growth of personalized medicine as a paradigm in healthcare that contributes to the continued use of ELISA in hospital settings. The global personalized medicine sales are projected to reach USD 3.2 trillion by 2027, according to a report.

Our in-depth analysis of the global market includes the following segments: